Survivin inhibitors |
YM155 (survivin suppressor) together with Paclitaxel and carboplatin |
Solid tumors and advanced non-small cell lung carcinoma |
I/II |
NCT01100931 |
Terameprocol (EM1421), inhibitor of survivin and cdc2 (cyclin-dependent kinase-1) in continuous intravenous infusion |
Refractory Solid tumors |
I |
NCT00664586 |
EZN-3042, a locked nucleic acid antisense oligonucleotide |
Acute Lymphoblastic Leukemia |
I |
NCT01186328 |
Terameprocol (EM-1421), inhibitor of survivin and cdc2 (cyclin-dependent kinase-1) |
Leukemia |
I |
NCT00664677 |
EZN-3042, a survivin-targeted mRNA antagonist, alone or in combination with standard chemotherapy |
Acute Lymphoblastic Leukemia |
I |
NCT01186328 |
LY2181308, an antisense oligonucleotid, targeted against survivin mRNA in combination with idarubicin and cytarabine |
Acute Myeloid Leukemia |
II |
NCT00620321 |
Survivin-based Cellular Therapy |
Dendritic cell vaccine (mRNA from PSA, PAP, survivin and hTERT) plus docetaxel or docetaxel alone |
Prostate Cancer (castration resistant and metastatic) |
II |
NCT01446731 |
Dendritic cells - transfected with hTERT-, survivin- and tumor cell derived mRNA + ex vivo T cell expansion and reinfusion |
Melanoma |
I/II |
NCT00961844 |
Drug: Temozolomide |
Procure®, denditric cells loaded with Survivin-peptide and Telomerase mRNA |
Ovarian Cancer |
I |
NCT01456065 |
Dendritic cell loaded with amplified ovarian cancer stem cell mRNA, hTERT/survivin mRNA |
Ovarian Cancer |
I/II |
NCT01334047 |
Cell therapy based on dendritic cells transfected with Survivin, hTERT and p53 mRNA |
Metastatic breast cancer |
I |
NCT00978913 |
Malignant melanoma |
TAA-SPECIFIC CTLs targeting survivin, PRAME, NY-ESO-1, MAGEA4 and SSX |
Solid Tumors (TACTASOM) |
I |
NCT02239861 |
Treatment with autologous dendritic cells transfected with Survivin, MelanA and MAGE-A3 mRNA or loaded with MAGE-A3, MelanA and Survivin |
Melanoma |
I/II |
NCT00074230 |
Cell therapy with cytotoxic T lymphocytes exposed to tumor associated antigens: NY-ESO-1, MAGEA4, PRAME, Survivin and SSX. |
Hodgkin or Non-Hodgkin Lymphoma |
I |
NCT01333046 |
TAA-CTLs may be generated from donors or recipients and will be tested for specificity against 4 tumor antigens commonly found in hematological malignancies (WT1, PRAME, SURVIVIN, and MAGE-A3). |
|
I |
NCT02203903 |
Hematological |
|
|
Malignancies |
Dendritic cell vaccine (MUC-1 and survivin) in combination with cytokine-induced killer cells |
Soft Tissue Sarcoma |
I/II |
NCT01898663 |
Dendritic cell vaccine (MUC-1 and survivin) in combination with cytokine-induced killer cells |
Renal Cell Carcinoma |
I/II |
NCT01924156 |
Autologous dendritic cell vaccine (peptides from survivin and telomerase) |
Renal Cell Carcinoma |
I/II |
NCT00197860 |
Multiple antigen specific cellular therapy: autologous T cytotoxic cells induced by dendritic cells (loaded with p53, her2, survivin and a total of 17 antigens) |
Hepatocellular Carcinoma |
I/II |
NCT02026362 |
Vaccine therapy (p53, survivin and telomerase) with autologous dendritic cells in combination with adjuvant cytokines |
Advanced Melanoma |
I/II |
NCT00197912 |
Multiple tumor-associated antigen (TAA)-specific T cells (against WT1, PRAME and survivin) from donors |
Acute Lymphoblastic Leukemia |
I |
NCT02475707 |
Multiple tumor-associated antigen (TAA)-specific T cells (against WT1, NY-ESO-1, PRAME and survivin) from donors |
Acute Lymphoblastic Leukemia/Myelodisplasic Syndrome |
I |
NCT02494167 |
Multiple tumor-associated antigen (TAA)-specific cytotoxic T cells (against NY-ESO-1, IMAGEA4, PRAME, SSX and survivin) from donors |
Multiple Myeloma |
I |
NCT02291848 |
Survivin-vaccines |
Survivin peptide vaccination in combination with sargramostin |
Malignant Glioma |
I |
NCT01250470 |
Vaccination with DPX-Survivin in combination with low doses of cyclophosphamide (The peptide antigens targeting survivin) |
Advanced Stage Ovarian, Fallopian or Peritoneal Cancer |
I/II) |
NCT01416038 |
hTERT/survivin/CMV multipeptide vaccine |
Breast Cancer |
Not provided |
NCT01660529 |
Multipeptide vaccination including survivin-peptide |
Multiple Myeloma |
I/II |
NCT00499577 |
SurVaxM Vaccine (survivin-peptide vaccine) in combination with temozolamide |
Glioblastoma |
II |
NCT02455557 |
Peptide vaccine (IDO/survivine peptide) as enhancer of temozolomide chemotherapy |
Metastatic Melanoma |
II |
NCT01543464 |
Vaccine therapy (MART1 analog, gp100 and survivin) and GM-CSF with or without Aldesleukin |
Melanoma |
I |
NCT00470015 |
Vaccine therapy (survivin) in patients receiving lenalidomide |
Multiple Myeloma |
I |
NCT02334865 |
hTERT tumor vaccine (peptides from telomerase, survivin and cytopeptide) in combination with autologous T cell infusion |
Multiple Myeloma |
I/II |
NCT00834665 |
Immunotherapeutic vaccine DPX-Survivac (targeting survivin) in combination with cyclophosphamide |
Diffuse Large B-Cell Lymphoma |
II |
NCT02323230 |
Survivin and telomerase peptide vaccination in combination with Daclizumab and Prevnar |
Advanced Breast cancer |
I |
NCT00573495 |
Survivin peptide vaccination |
Advanced Melanoma, pancreatic, colon and cervical cancer |
I/II |
NCT00108875 |